Focal therapy for localized prostate cancer —choosing the middle ground

摘要: Prostate cancer (PCa) is the most common noncutaneous human malignancy, with an estimated 24 700 cases diagnosed in 2008 Canada.1 Autopsy studies have demonstrated PCa 40% of men aged 60 years, increasing up to 70% 80 years. However, lifetime risk clinically significant and fatal prostate a 50-year-old man be only 9.5% 2.9%, respectively.2 Some patients high-grade high-volume disease will require treatment, but we are uncertain treatment requirements without such features. Hence dilemma raised: Should overtreat many whole-gland radical treatments who ultimately insignificant disease, or should select active surveillance (AS) potentially miss window opportunity for cure those treatment? The aim this article highlight some shortcomings both these options carefully selected population offer new option, focal therapy, that would better risk–benefit balance thus serve as superior middle ground management PCa.